Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

BioNTech (BNTX) on Friday announced separate agreements with the US National Institutes of Health and the University of Pennsylvania to settle royalty claims related to sales of its COVID-19 ...

Dec 27 (Reuters) - BioNTech (22UAy.DE), opens new tab has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

BioNTech and its partner US pharmaceutical giant Pfizer are to pay a total of a €1.2 billion ($1.3 billion) to the US health agency and the University of Pennsylvania, BioNTech said. The ...

(RTTNews) - BioNTech SE (BNTX), Friday reached two separate settlements with the U.S. National Institutes of Health, and the University of Pennsylvania regarding the royalties payment of COVID-19 ...

BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B with the National Institutes of Health (NIH) and the University of Pennsylvania to resolve royalty and other ...

Truist sets BioNTech's price target at $172, highlighting BNT327's revenue potential of $6B+ across multiple cancer indications. BioNTech's BNT327 could lead U.S. and European approvals for key ...

BioNTech SE ( (BNTX)) has provided an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly ...